Imugene Ltd (ASX:IMU)


Imugene is an Australian biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies.

The company has a worldwide exclusive license agreement to develop the Her-Vaxx vaccine that was developed at The Medical University of Vienna. Her-Vaxx has the ability to stimulate the body's immune system to produce Herceptin, which assists in fighting breast and gastric cancer.

Forrest Capital's Role:

Forrest associates were substantial shareholders in the Australian vaccine company Biolife Science Ltd.

  • Forrest negotiated the acquisition of Biolife by IMU.
  • Conducted associated capital raising totalling $11 million.
  • Facilitated the appointment of Dr Axel Hoos, Ms Leslie Chong and Mr Otto Buttula to the company.